Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis.
This randomized double-blind placebo controlled study assessed the vaginal colonization of lactic acid bacteria and clinical outcome. Vaginal capsules containing L gasseri LN40, Lactobacillus fermentum LN99, L. casei subsp. rhamnosus LN113 and P. acidilactici LN23, or placebos were administered for five days to 95 women after conventional treatment of bacterial vaginosis and/or vulvovaginal candidiasis. Vulvovaginal examinations and vaginal samplings were performed before and after administration, after the first and second menstruation, and after six months. Presence of LN strains was assessed using RAPD analysis. LN strains were present 2-3 days after administration in 89% of the women receiving LN strains (placebo: 0%, p < 0.0001). After one menstruation 53% were colonized by at least one LN strain. Nine percent were still colonized six months after administration. Ninety-three percent of the women receiving LN strains were cured 2-3 days after administration (placebo: 83%), and 78% after one menstruation (placebo: 71%) (ns). The intervention group experienced less malodorous discharge 2-3 days after administration (p = 0.03) and after the second menstruation (p = 0.04), compared with placebo. In summary, five days of vaginal administration of LN strains after conventional treatment of bacterial vaginosis and/or vulvovaginal candidiasis lead to vaginal colonization, somewhat fewer recurrences and less malodorous discharge.
Ehrström
Sophia
S
Karolinska Institutet, Department of Clinical Sciences, Division of Obstetrics and Gynecology, Danderyd Hospital, Stockholm, PA 182 88, Sweden. sophia.ehrstrom@ds.se
Daroczy
Katalin
K
Rylander
Eva
E
Samuelsson
Carolina
C
Johannesson
Ulrika
U
Anzén
Bo
B
Påhlson
Carl
C
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D016172:DNA Fingerprinting; D004269:DNA, Bacterial / Q000235:genetics / Q000302:isolation & purification; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007778:Lactobacillus / Q000145:classification / Q000254:growth & development / Q000302:isolation & purification / Q000502:physiology*; D008875:Middle Aged; D010376:Pediococcus / Q000145:classification / Q000254:growth & development / Q000302:isolation & purification / Q000502:physiology*; D019936:Probiotics / Q000008:administration & dosage*; D019105:Random Amplified Polymorphic DNA Technique; D055502:Secondary Prevention; D016896:Treatment Outcome; D014621:Vagina / Q000382:microbiology; D016585:Vaginosis, Bacterial / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D014844:Vulva / Q000382:microbiology; D055815:Young Adult
D000890:Anti-Infective Agents; D004269:DNA, Bacterial